Heparin Monitoring with an Anti-Xa Protocol Compared to Activated Clotting Time in Patients on Temporary Mechanical Circulatory Support.

Joel T FeihKirsten E WallskogJoseph R G RinkaJanelle J JuulLisa ReinNunzio GaglianelloLisa M Baumann KreuzigerDavid L JoyceJustin N Tawil

Published in: The Annals of pharmacotherapy (2021)

Anti-Xa monitoring was associated with a lower hazard of bleeding during tMCS compared to an ACT-based protocol. Further studies should evaluate if anti-Xa monitoring should be preferentially used in tMCS.

Keyphrases

end stage renal disease
randomized controlled trial
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
venous thromboembolism
atrial fibrillation
patient reported outcomes
growth factor